AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34446679 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) initiation
Number of subjects: 1177
Study 34446679 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up for ≥12 months
Number of subjects: 1177
Study 34446679 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality rate
Number of subjects: 1177
Study 34446679 — intervention group
Group type: EXPERIMENTAL
Intervention: Causes of death
Number of subjects: 1177
Study 34446679 — intervention group
Group type: EXPERIMENTAL
Intervention: Deaths among CrAg-positive individuals
Number of subjects: 1177
Study 34446728 — intervention group
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Number of subjects: 73
Study 34446764 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation
Number of subjects: 1742
Study 34447323 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral Transcranial Photobiomodulation
Number of subjects: 0
Study 34448184 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein signature for PDAC screening
Number of subjects: 58
Study 34448184 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein signature score (PSS) combined with patient age
Number of subjects: 58
Study 34448184 — intervention group
Group type: EXPERIMENTAL
Intervention: PSS
Number of subjects: 58
Study 34448185 — intervention group
Group type: EXPERIMENTAL
Intervention: Location-based resect-and-discard strategy
Number of subjects: 1117
Study 34448185 — intervention group
Group type: COMPARATOR
Intervention: Optical diagnosis using NICE classification
Number of subjects: 1117
Study 34448185 — intervention group
Group type: COMPARATOR
Intervention: Optical diagnosis using Sano classification
Number of subjects: 1117
Study 34448598 — intervention group
Group type: EXPERIMENTAL
Intervention: FGF21 level measurement
Number of subjects: 0
Study 34448598 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney glucose uptake measurement
Number of subjects: 0
Study 34448665 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile application for self-management of IBD patients
Number of subjects: 55
Study 34448679 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI visual T-category
Number of subjects: 45
Study 34448679 — intervention group
Group type: EXPERIMENTAL
Intervention: VI-RADS score
Number of subjects: 45
Study 34448679 — intervention group
Group type: EXPERIMENTAL
Intervention: Both subjective MRI visual T-category and VI-RADS score
Number of subjects: 45
Study 34448726 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ VAS (Visual Analog Scale)
Number of subjects: 700000
Study 34448726 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D dimensions
Number of subjects: 700000
Study 34448726 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-assessed EQ VAS values
Number of subjects: 700000
Study 34448726 — intervention group
Group type: COMPARATOR
Intervention: General population VAS and time trade-off value sets
Number of subjects: 700000
Study 34448728 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation and correction of inhaler technique using device-specific checklists for 13 inhaler types.
Number of subjects: 0
Study 34448728 — intervention group
Group type: COMPARATOR
Intervention: Use of an identical placebo device for observing inhaler technique.
Number of subjects: 0
Study 34448728 — intervention group
Group type: EXPERIMENTAL
Intervention: Technique optimization or switching to a suitable inhaler.
Number of subjects: 0
Study 34448755 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 168
Study 34448755 — intervention group
Group type: COMPARATOR
Intervention: Pain Education (EDU)
Number of subjects: 168
Study 34448816 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Time-Warped Pearson Correlations (DTW-PC)
Number of subjects: 81
Study 34448816 — intervention group
Group type: EXPERIMENTAL
Intervention: Pearson Correlations (PC)
Number of subjects: 81
Study 34448816 — intervention group
Group type: EXPERIMENTAL
Intervention: Support Vector Machine (SVM) classification
Number of subjects: 81
Study 34448930 — intervention group
Group type: EXPERIMENTAL
Intervention: New-onset neurological symptoms (NNS)
Number of subjects: 10881
Study 34449252 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Image After Mastectomy Scale
Number of subjects: 0
Study 34449258 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34449262 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-Mounted Display Virtual Reality Games
Number of subjects: 0
Study 34449807 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to vigorous physical activity (MVPA)
Number of subjects: 503
Study 34449807 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary time (ST)
Number of subjects: 503
Study 34449807 — intervention group
Group type: EXPERIMENTAL
Intervention: Total physical activity (PA)
Number of subjects: 503
Study 34449877 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab 3 mg/kg intravenously
Number of subjects: 151
Study 34449941 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive Care (SC) needs assessment using SCNS-SF34 before radical cystectomy and at 1, 3, 6, and 12 months post-surgery.
Number of subjects: 90
Study 34449941 — intervention group
Group type: EXPERIMENTAL
Intervention: Utilization of SC services and willingness to use SC services.
Number of subjects: 90
Study 34451560 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34452642 — intervention group
Group type: EXPERIMENTAL
Intervention: COPESS plus treatment as usual (TAU)
Number of subjects: 60
Study 34452642 — intervention group
Group type: COMPARATOR
Intervention: TAU alone
Number of subjects: 60
Study 34452981 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Community-Based Health Systems-Strengthening (ICBHSS) initiative
Number of subjects: 10022
Study 34453044 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab and entinostat
Number of subjects: 29
Study 34453203 — intervention group
Group type: EXPERIMENTAL
Intervention: ODAP-Urea-based ligands
Number of subjects: 0
Study 34453241 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurbinectedin and cisplatin combination with aprepitant (Group A)
Number of subjects: 0
Study 34453241 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurbinectedin and cisplatin combination without aprepitant (Group B)
Number of subjects: 0
Study 34453519 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-positive donors
Number of subjects: 92
Study 34453569 — intervention group
Group type: EXPERIMENTAL
Intervention: Health awareness
Number of subjects: 229
Study 34453569 — intervention group
Group type: EXPERIMENTAL
Intervention: Body change concerns
Number of subjects: 229
Study 34453569 — intervention group
Group type: EXPERIMENTAL
Intervention: Life interferences
Number of subjects: 229
Study 34453569 — intervention group
Group type: EXPERIMENTAL
Intervention: Worry
Number of subjects: 229
Study 34453622 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical impedance tomography (EIT) with saline bolus (10 ml 10% NaCl injection) during a respiratory hold
Number of subjects: 108
Study 34453622 — intervention group
Group type: COMPARATOR
Intervention: Control group (15 patients without ARF)
Number of subjects: 108
Study 34453682 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 203
Study 34454047 — intervention group
Group type: EXPERIMENTAL
Intervention: Frameless unilateral radiosurgical ablation of the thalamic ventral intermediate nucleus to a maximum dose of 160 Gy
Number of subjects: 33
Study 34454420 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Number of subjects: 1777
Study 34454420 — intervention group
Group type: COMPARATOR
Intervention: Mild pain
Number of subjects: 1777
Study 34454432 — intervention group
Group type: EXPERIMENTAL
Intervention: Zika virus infection
Number of subjects: 427
Study 34454432 — intervention group
Group type: EXPERIMENTAL
Intervention: Dengue virus infection
Number of subjects: 427
Study 34454432 — intervention group
Group type: EXPERIMENTAL
Intervention: Unidentified pathogen (UIE)
Number of subjects: 427
Study 34454460 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstring muscle evaluation at velocities of 60 and 180 deg/s
Number of subjects: 33
Study 34454460 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstring muscle evaluation in patients with one-sided dislocation
Number of subjects: 33
Study 34454460 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee flexors strength evaluation in recurrent patellar dislocation patients
Number of subjects: 33
Study 34454573 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT) sessions, exercising at 30% of MIP, two daily sessions for 3 weeks.
Number of subjects: 80
Study 34454573 — intervention group
Group type: COMPARATOR
Intervention: Conventional neurorehabilitation (usual practice)
Number of subjects: 80
Study 34454591 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-HOBA
Number of subjects: 162
Study 34454591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study 34454592 — intervention group
Group type: EXPERIMENTAL
Intervention: TIMP with rhythm
Number of subjects: 100
Study 34454592 — intervention group
Group type: EXPERIMENTAL
Intervention: TIMP without rhythm
Number of subjects: 100
Study 34454592 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of care occupational therapy (OT)
Number of subjects: 100
Study 34454592 — intervention group
Group type: COMPARATOR
Intervention: Waitlisted (control)
Number of subjects: 100
Study 34454594 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard usual care combined with in-bed cycling
Number of subjects: 210
Study 34454594 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard usual care combined with exercises from a booklet
Number of subjects: 210
Study 34454594 — intervention group
Group type: COMPARATOR
Intervention: Standard usual care
Number of subjects: 210
Study 34454636 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie diet (LCD)
Number of subjects: 31
Study 34454637 — intervention group
Group type: EXPERIMENTAL
Intervention: Deliberative loop intervention with stakeholders (providers and staff) including background information, facilitated small-group discussions, and sharing informed opinions with clinic leaders.
Number of subjects: 16
Study 34454637 — intervention group
Group type: EXPERIMENTAL
Intervention: Deliberative loop intervention
Number of subjects: 16
Study 34454787 — intervention group
Group type: EXPERIMENTAL
Intervention: ACAM2000 smallpox vaccine
Number of subjects: 897227
Study 34454787 — intervention group
Group type: COMPARATOR
Intervention: Dryvax smallpox vaccine
Number of subjects: 897227
Study 34454994 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO-C3
Number of subjects: 517
Study 34454994 — intervention group
Group type: EXPERIMENTAL
Intervention: ADAPT
Number of subjects: 517
Study 34455067 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib 150 mg twice daily and trametinib 2 mg once daily (cohort B)
Number of subjects: 93
Study 34455067 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib 150 mg twice daily and trametinib 2 mg once daily (cohort C)
Number of subjects: 93
Study 34455112 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-rich plaques detected by near-infrared spectroscopy (NIRS) and intravascular ultrasound (IVUS)
Number of subjects: 1551
Study 34455112 — intervention group
Group type: COMPARATOR
Intervention: Age groups (<50, 50-64, 65-74, ≥75)
Number of subjects: 1551
Study 34455263 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate supplementation (n = 168)
Number of subjects: 379
Study 34455263 — intervention group
Group type: COMPARATOR
Intervention: No folate supplementation (n = 184)
Number of subjects: 379
Study 34455857 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI)
Number of subjects: 0
Study 34455857 — intervention group
Group type: COMPARATOR
Intervention: Bioprosthetic surgical aortic valve replacement (SAVR)
Number of subjects: 0
Study 34456057 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid
Number of subjects: 565
Study 34457038 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral masitinib (4.5 mg/kg/day)
Number of subjects: 0
Study 34457038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34457743 — intervention group
Group type: EXPERIMENTAL
Intervention: One-day laparoscopic skills workshop
Number of subjects: 33
Study 34457749 — intervention group
Group type: EXPERIMENTAL
Intervention: UTHealth trainees
Number of subjects: 3248
Study 34457876 — intervention group
Group type: EXPERIMENTAL
Intervention: BLS training with preparatory web-based education, instructor-led training, film-based instructions, reflective questions, and chest compression feedback device
Number of subjects: 0
Study 34457876 — intervention group
Group type: COMPARATOR
Intervention: Standard BLS training
Number of subjects: 0
Study 34458156 — intervention group
Group type: EXPERIMENTAL
Intervention: Stool consistency measured by the Bristol Stool Scale (BSS) and fecal dry weight percentage
Number of subjects: 24
Study 34458156 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbial community structure analysis (beta diversity)
Number of subjects: 24
Study 34458156 — intervention group
Group type: EXPERIMENTAL
Intervention: Single fecal sampling
Number of subjects: 24
Study 34458717 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection port of ported PVCs
Number of subjects: 300
Study 34458717 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal lumen of ported PVCs
Number of subjects: 300
Study 34458717 — intervention group
Group type: EXPERIMENTAL
Intervention: Both port and internal lumen of ported PVCs
Number of subjects: 300
Study 34459237 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged high-intensity endurance exercise (first race)
Number of subjects: 59
Study 34459237 — intervention group
Group type: COMPARATOR
Intervention: Cardiopulmonary exercise test (least strenuous exercise)
Number of subjects: 59
Study 34459317 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza A/Singapore/INFIMH-16-0019/2016(H3N2)-like virus vaccine
Number of subjects: 162
Study 34459500 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial breast irradiation (PBI) / Accelerated partial breast irradiation (APBI)
Number of subjects: 15187
Study 34460083 — intervention group
Group type: EXPERIMENTAL
Intervention: NaIHS (50 mg ibuprofen, tid)
Number of subjects: 383
Study 34460083 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 383
Study 34460829 — intervention group
Group type: EXPERIMENTAL
Intervention: SD Bioline HAT
Number of subjects: 3433
Study 34460829 — intervention group
Group type: EXPERIMENTAL
Intervention: HAT Sero-K-Set
Number of subjects: 3433
Study 34460829 — intervention group
Group type: EXPERIMENTAL
Intervention: rHAT Sero-Strip
Number of subjects: 3433
Study 34460829 — intervention group
Group type: EXPERIMENTAL
Intervention: LAMP and ELISA/Tbg
Number of subjects: 3433
Study 34460829 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic tests (general)
Number of subjects: 3433
Study 34461299 — intervention group
Group type: EXPERIMENTAL
Intervention: PBC patients
Number of subjects: 112
Study 34461303 — intervention group
Group type: EXPERIMENTAL
Intervention: History of smoking and/or alcohol consumption (positive gene mutation group)
Number of subjects: 798
Study 34461303 — intervention group
Group type: EXPERIMENTAL
Intervention: History of smoking and/or alcohol consumption (negative gene mutation group)
Number of subjects: 798
Study 34461303 — intervention group
Group type: COMPARATOR
Intervention: Patients with gene mutations (with and without alcohol/smoking status)
Number of subjects: 798
Study 34461303 — intervention group
Group type: EXPERIMENTAL
Intervention: Age at onset of CP
Number of subjects: 798
Study 34461303 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 798
Study 34461303 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 798
Study 34461303 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 798
Study 34461561 — intervention group
Group type: EXPERIMENTAL
Intervention: High eicosapentaenoic acid multinutrient supplement (1125 mg eicosapentaenoic acid, 441 mg docosahexaenoic acid, 330 mg magnesium, 7.5 mg vitamin E)
Number of subjects: 0
Study 34461561 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34461936 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational weight gain (GWG) recommendations based on pre-pregnancy BMI
Number of subjects: 3172
Study 34461936 — intervention group
Group type: EXPERIMENTAL
Intervention: GWG of ≥14 kg and <16 kg
Number of subjects: 3172
Study 34461936 — intervention group
Group type: EXPERIMENTAL
Intervention: GWG of ≥10 kg and <12 kg
Number of subjects: 3172
Study 34461936 — intervention group
Group type: EXPERIMENTAL
Intervention: GWG of ≥12 kg and <14 kg
Number of subjects: 3172
Study 34461936 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse pregnancy outcomes for underweight women
Number of subjects: 3172
Study 34461936 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse pregnancy outcomes for normal weight women
Number of subjects: 3172
Study 34461936 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse pregnancy outcomes for overweight women
Number of subjects: 3172
Study 34461936 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse pregnancy outcomes for obese women
Number of subjects: 3172
Study 34462004 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-sampling (urine and vaginal)
Number of subjects: 515
Study 34462004 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-sampling (urine)
Number of subjects: 515
Study 34462004 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-sampling (vaginal with cotton swabs)
Number of subjects: 515
Study 34462004 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-sampling (vaginal with plastic brushes)
Number of subjects: 515
Study 34462004 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-sampling
Number of subjects: 515
Study 34462004 — intervention group
Group type: COMPARATOR
Intervention: Clinician-collected sample
Number of subjects: 515
Study 34462007 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine infusion 1-2 μg/kg/min for 48 hours
Number of subjects: 83
Study 34462007 — intervention group
Group type: COMPARATOR
Intervention: Standard of care alone (Control Group)
Number of subjects: 83
Study 34462008 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored discussion guide (TDG) and brief provider training
Number of subjects: 44
Study 34462008 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 44
Study 34462189 — intervention group
Group type: EXPERIMENTAL
Intervention: GLS-010 (zimberelimab) 240 mg, intravenous, once every 2 weeks until progression, death, unacceptable toxicity, or consent withdrawal
Number of subjects: 85
Study 34462238 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone withdrawal
Number of subjects: 10
Study 34462271 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital service model for high-risk COPD patients
Number of subjects: 0
Study 34462271 — intervention group
Group type: COMPARATOR
Intervention: Current standards of care
Number of subjects: 0
Study 34462327 — intervention group
Group type: EXPERIMENTAL
Intervention: Bintrafusp alpha (dual PD-L1 and TGF-b blockade)
Number of subjects: 8
Study 34462327 — intervention group
Group type: COMPARATOR
Intervention: Avelumab (PD-L1 blockade)
Number of subjects: 8
Study 34462327 — intervention group
Group type: EXPERIMENTAL
Intervention: TGF-b neutralization
Number of subjects: 8
Study 34462327 — intervention group
Group type: COMPARATOR
Intervention: PD-L1 blockade alone
Number of subjects: 8
Study 34462560 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive equations (PEs) developed from acute phase data using indirect calorimetry measurements.
Number of subjects: 474
Study 34462560 — intervention group
Group type: EXPERIMENTAL
Intervention: Best predictive equation for REE: 891.6(Height) + 9.0(Weight) + 39.7(Minute Ventilation) - 5.6(Age) - 354.
Number of subjects: 474
Study 34462732 — intervention group
Group type: EXPERIMENTAL
Intervention: icosapent ethyl (8 g daily for 3 days followed by 4 g daily for 11 days)
Number of subjects: 100
Study 34462732 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 100
Study 34462760 — intervention group
Group type: EXPERIMENTAL
Intervention: CD24Fc treatment
Number of subjects: 22
Study 34462760 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 34463622 — intervention group
Group type: EXPERIMENTAL
Intervention: WYZ mobile health app
Number of subjects: 79
Study 34463717 — intervention group
Group type: EXPERIMENTAL
Intervention: LAA filling defects
Number of subjects: 1621
Study 34463717 — intervention group
Group type: COMPARATOR
Intervention: Normal LAA filling
Number of subjects: 1621
Study 34463717 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus-like pattern
Number of subjects: 1621
Study 34463717 — intervention group
Group type: EXPERIMENTAL
Intervention: HU-run-off pattern
Number of subjects: 1621
Study 34463717 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterogeneous pattern
Number of subjects: 1621
Study 34463717 — intervention group
Group type: EXPERIMENTAL
Intervention: Horizontal pattern
Number of subjects: 1621
Study 34463835 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise (TE) intervention, delivered twice a week for 3 months, consisting of 1 hour of TE and 30 minutes of nutritional education
Number of subjects: 158
Study 34463905 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with TRD
Number of subjects: 1475
Study 34463905 — intervention group
Group type: COMPARATOR
Intervention: Patients without TRD
Number of subjects: 1475
Study 34464029 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg q.d.
Number of subjects: 1916
Study 34464029 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg q.d.
Number of subjects: 1916
Study 34464029 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 1916
Study 34464155 — intervention group
Group type: EXPERIMENTAL
Intervention: AUTO1 (autologous CAT19-41BB-Z CAR T cells)
Number of subjects: 20
Study 34464163 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratumoral Coxsackievirus A21 (V937)
Number of subjects: 57
Study 34464408 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-group with preterm birth (RG-PB)
Number of subjects: 284
Study 34464408 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-group with term birth (RG-TB)
Number of subjects: 284